Keyang Xu

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. doi request reprint Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 5:1057-71. 2013
  2. doi request reprint Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry
    Keyang Xu
    Genentech, South San Francisco, CA 94080, USA
    Anal Biochem 412:56-66. 2011
  3. doi request reprint Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    Ben Quan Shen
    Genentech Inc, 1 DNA Way, S San Francisco, California, USA
    Nat Biotechnol 30:184-9. 2012
  4. doi request reprint Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
    Surinder Kaur
    Genentech, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    Bioanalysis 5:201-26. 2013
  5. doi request reprint A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 6:1781-94. 2014
  6. doi request reprint Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering
    Thomas H Pillow
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, United States
    J Med Chem 57:7890-9. 2014
  7. pmc A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer
    Brendan Bender
    Department of Clinical Pharmacology, Genentech Inc, South San Francisco, California, USA
    AAPS J 16:994-1008. 2014

Collaborators

Detail Information

Publications7

  1. doi request reprint Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 5:1057-71. 2013
    ..The objective of this manuscript was to propose and assess the assays that allow for the characterization of the drug deconjugation in plasma/serum...
  2. doi request reprint Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry
    Keyang Xu
    Genentech, South San Francisco, CA 94080, USA
    Anal Biochem 412:56-66. 2011
    ..Other potential applications of the method may include characterization of posttranslational modifications, protein adducts, and immunogenicity...
  3. doi request reprint Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    Ben Quan Shen
    Genentech Inc, 1 DNA Way, S San Francisco, California, USA
    Nat Biotechnol 30:184-9. 2012
    ..Thus, the chemical and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface...
  4. doi request reprint Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
    Surinder Kaur
    Genentech, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    Bioanalysis 5:201-26. 2013
    ..Our strategy has involved novel protein structural characterization tools to help understand ADC biotransformations in vivo and use of the analyte knowledge gained to guide the development of quantitative bioanalytical assays...
  5. doi request reprint A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study
    Keyang Xu
    Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Bioanalysis 6:1781-94. 2014
    ..However, these studies present bioanalytical challenges for ligand-binding assays (LBAs). Recent MS-based protein quantification offers an alternative for bioanalysis...
  6. doi request reprint Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering
    Thomas H Pillow
    Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, United States
    J Med Chem 57:7890-9. 2014
    ....
  7. pmc A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer
    Brendan Bender
    Department of Clinical Pharmacology, Genentech Inc, South San Francisco, California, USA
    AAPS J 16:994-1008. 2014
    ..The two modeling approaches provide flexibility based on available analytical measurements for T-DM1 and a framework for designing ADC studies and PK-pharmacodynamic modeling of ADC efficacy- and toxicity-related endpoints...